{Reference Type}: Journal Article
{Title}: Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
{Author}: Aydoğan Bİ;Ünlütürk U;Cesur M;Aydoğan Bİ;Ünlütürk U;Cesur M;
{Journal}: Endocrine
{Volume}: 78
{Issue}: 1
{Year}: Oct 2022
{Factor}: 3.925
{DOI}: 10.1007/s12020-022-03130-8
{Abstract}: <B>OBJECTIVE: </B>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.<BR><B>METHODS: </B>We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.<BR><B>RESULTS: </B>In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.<BR><B>CONCLUSIONS: </B>Vaccination with BNT162b2 may trigger type 1 diabetes.